CD19 and lymphoma: The following clinical trials using CRISPR-edited T cells are also ongoing: TRAC/B2M KO CD19 CAR T cells for B-cell leukemia and lymphoma (NCT03166878; NCT03229876); TRAC/PD1 KO mesothelin CAR T cells for solid tumors (NCT03545815); TRAC KO dual CD19/CD22 and CD19/CD20 CAR T cells for B-cell leukemia (NCT03398967); CD19 TCR-CAR T cells for non-Hodgkin lymphoma and B-cell ALL using meganucleases (NCT03666000).